Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib in Advanced Hepatocellular Cancer
NCT01807156Phase 2Terminated
- Sponsor
- Emory University
- Start
- Mar 2013
- Primary completion
- Feb 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tivozanib in hepatocellular carcinoma (HCC), sponsored by Emory University. Started Mar 2013; status: terminated.
02
Drugs
tivozanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01807156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01807156.